|
|
 |
|
Viewing report
|
|
|
|
U.S. Insomnia Therapies Markets
Frost & Sullivan, April 2004
In the last few years, drug manufacturers have been making concerted efforts at raising patient and physician awareness about the serious implications of insomnia. These efforts are now beginning to pay off. More and more people are seeking medical help for their sleeping problems. However, the full potential of the market has not yet been realized. Though there are over 50 million insomniacs in the United States that need treatment, only about 10 million use prescription sleep aids.
Sleep aids are likely to get a huge boost from the clinical trials that have been carried out by companies set to enter the market. Scheduled medications are indicated only for short-term treatment since tolerance and dependence could develop. Patients are warned not to use products such as Ambien and Sonata for more than a month. However, as the prevalence of chronic insomnia continues to rise, both physicians and the FDA are on the lookout for effective medications to combat the problem. Data from long-term clinical trials for Estorra and indiplon have shown that non-benzodiazepines neither lose their efficacy over time nor cause serious side effects.
|
|
|
|
